The company’s portfolio now includes molecular diagnostic solutions with CE-IVDR marking for different areas of clinical genetics.
Genetic diagnostics has been taking on an increasingly relevant role in precision medicine, enabling support for faster, more rigorous and personalised clinical decisions in areas such as hereditary diseases, fertility, oncology and transplantation. In this context, Quilaban has established a partnership with Devyser to integrate into its portfolio a set of molecular diagnostic solutions with CE-IVDR marking.
Specialising in the development of genetic tests for clinical diagnostics, Devyser provides solutions for different applications, including hereditary diseases, cystic fibrosis (CFTR), thalassemias, male infertility, chromosomal aneuploidies and post-transplant monitoring. Present in more than 65 countries, the company develops technologies that simplify laboratory workflows and support the achievement of rapid and reliable results.
The solutions made available through this partnership enable laboratories to perform genetic tests with high precision, supporting the identification of clinically relevant genetic alterations and contributing to more informed clinical decisions. The CE-IVDR marking of these solutions is also an added value for laboratories seeking technologies aligned with current European regulatory requirements.
“The evolution of the European regulatory framework requires that laboratories can rely on solutions that reconcile technological innovation and regulatory compliance. The partnership with Devyser enables the Portuguese market to have access to a comprehensive portfolio of genetic tests already certified under IVDR, contributing to strengthening diagnostic quality and supporting laboratories in responding to current precision medicine challenges”, states Sónia Pereira, Product and Applications Manager at Quilaban.
Through this partnership, Portuguese laboratories now have access, through Quilaban, to an expanded portfolio of molecular diagnostic solutions developed to meet current requirements of clinical genetics. This collaboration expands the available offering for different application areas and supports the evolution of genetic diagnostics and precision medicine in Portugal.
